PRINCETON, N.J., Sept. 8 /PRNewswire-FirstCall/ -- DOR BioPharma, Inc., a late-stage biotechnology
company, announced today that the National Institutes of Health (NIH) has
awarded DOR a Small Business Innovation Research (SBIR) grant to support the
conduct of a Phase 1/2 clinical trial evaluating DOR201, a time-release
formulation of oral beclomethasone dipropionate (oral BDP), for the prevention
of acute radiation enteritis. The award will provide DOR with approximately
$500,000 over a two-year period.
